AstraZeneca: 79% vaccine efficacy in phase 3 trial
(CercleFinance.com) - AstraZeneca announced on Monday that its Covid-19 vaccine showed up to a 100% efficacy in a phase III clinical trial in the US.
The efficacy of the vaccine, called AZD1222, was measured at 79%, a rate considered "significant", in preventing symptomatic forms of the disease.
In the prevention of severe forms of the disease and hospitalisations, the vaccine's efficacy rate was 100%, the laboratory said in a statement.
In particular, AstraZeneca mentions an efficacy of 80% in the over 65s.
The group added that the vaccine was well tolerated and that the independent committee that monitored the study did not identify any increased risk of thrombosis or thrombotic events in the 21,583 participants who received at least one dose of the vaccine.
In London, AstraZeneca shares were up 0.8% on Monday morning, outperforming the FTSE 100 index, which was down 0.3%.
Copyright (c) 2021 CercleFinance.com. All rights reserved.
The efficacy of the vaccine, called AZD1222, was measured at 79%, a rate considered "significant", in preventing symptomatic forms of the disease.
In the prevention of severe forms of the disease and hospitalisations, the vaccine's efficacy rate was 100%, the laboratory said in a statement.
In particular, AstraZeneca mentions an efficacy of 80% in the over 65s.
The group added that the vaccine was well tolerated and that the independent committee that monitored the study did not identify any increased risk of thrombosis or thrombotic events in the 21,583 participants who received at least one dose of the vaccine.
In London, AstraZeneca shares were up 0.8% on Monday morning, outperforming the FTSE 100 index, which was down 0.3%.
Copyright (c) 2021 CercleFinance.com. All rights reserved.